The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes - PubMed (original) (raw)

Review

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Daniel J Drucker et al. Lancet. 2006.

Abstract

Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food intake. Therapeutic approaches for enhancing incretin action include degradation-resistant GLP-1 receptor agonists (incretin mimetics), and inhibitors of dipeptidyl peptidase-4 (DPP-4) activity (incretin enhancers). Clinical trials with the incretin mimetic exenatide (two injections per day or long-acting release form once weekly) and liraglutide (one injection per day) show reductions in fasting and postprandial glucose concentrations, and haemoglobin A1c (HbA1c) (1-2%), associated with weight loss (2-5 kg). The most common adverse event associated with GLP-1 receptor agonists is mild nausea, which lessens over time. Orally administered DPP-4 inhibitors, such as sitagliptin and vildagliptin, reduce HbA1c by 0.5-1.0%, with few adverse events and no weight gain. These new classes of antidiabetic agents, and incretin mimetics and enhancers, also expand beta-cell mass in preclinical studies. However, long-term clinical studies are needed to determine the benefits of targeting the incretin axis for the treatment of type 2 diabetes.

PubMed Disclaimer

Comment in

Gliptins.
Mikhail N. Mikhail N. Lancet. 2007 Jan 27;369(9558):269. doi: 10.1016/S0140-6736(07)60136-6. Lancet. 2007. PMID: 17258655 No abstract available.
Gliptins.
Focosi D, Kast RE, Petrini M. Focosi D, et al. Lancet. 2007 Jan 27;369(9558):269-70. doi: 10.1016/S0140-6736(07)60137-8. Lancet. 2007. PMID: 17258656 No abstract available.
Gliptins.
Grouzmann E, Buclin T, Biollaz J. Grouzmann E, et al. Lancet. 2007 Jan 27;369(9558):269. doi: 10.1016/S0140-6736(07)60135-4. Lancet. 2007. PMID: 17258657 No abstract available.

Cited by

Bitter taste receptors as sensors of gut luminal contents.
Sternini C, Rozengurt E. Sternini C, et al. Nat Rev Gastroenterol Hepatol. 2025 Jan;22(1):39-53. doi: 10.1038/s41575-024-01005-z. Epub 2024 Oct 28. Nat Rev Gastroenterol Hepatol. 2025. PMID: 39468215 Review.
Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.
Choy S, Hénin E, van der Walt JS, Kjellsson MC, Karlsson MO. Choy S, et al. J Pharmacokinet Pharmacodyn. 2013 Feb;40(1):1-10. doi: 10.1007/s10928-012-9281-1. Epub 2012 Nov 24. J Pharmacokinet Pharmacodyn. 2013. PMID: 23179858 Clinical Trial.
Incretin hormones and the satiation signal.
Holst JJ. Holst JJ. Int J Obes (Lond). 2013 Sep;37(9):1161-8. doi: 10.1038/ijo.2012.208. Epub 2013 Jan 8. Int J Obes (Lond). 2013. PMID: 23295502 Free PMC article. Review.
Coming full circle in diabetes mellitus: from complications to initiation.
Harcourt BE, Penfold SA, Forbes JM. Harcourt BE, et al. Nat Rev Endocrinol. 2013 Feb;9(2):113-23. doi: 10.1038/nrendo.2012.236. Epub 2013 Jan 8. Nat Rev Endocrinol. 2013. PMID: 23296171 Review.
Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Tahrani AA, Barnett AH, Bailey CJ. Tahrani AA, et al. Nat Rev Endocrinol. 2016 Oct;12(10):566-92. doi: 10.1038/nrendo.2016.86. Epub 2016 Jun 24. Nat Rev Endocrinol. 2016. PMID: 27339889 Review.

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes - PubMed (original) (raw)